Trials Sponsors Conditions Drugs Pricing

Conditions

Neurodegeneration REM Sleep Behavior Disorder

Keywords

α-synucleinopathyNeurodegenerationProdromal markersREM sleep behavior disorder

Outcome Measures

Primary Outcomes (1)

Changes of the overall probability of prodromal Parkinson's disease in the FDRs of patients with RBD.
Changes of the overall probability of prodromal Parkinson's disease will be calculated based on the Movement Disorder Society (MDS) research criteria for prodromal Parkinson's disease in the FDRs of patients with RBD.
Baseline and 5 years

Secondary Outcomes (3)

Changes of tonic EMG activity in the FDRs of patients with RBD.
Baseline and 5 years
Changes of physical activity level and circadian in the FDRs of patients with RBD.
Baseline and 5 years
New incidence of RBD and α-synucleinopathy in the FDRs of patients with RBD.
Baseline and 5 years

Study Arms (2)

FDRs of idiopathic RBD patients

First-degree relatives of idiopathic RBD patients

FDRs of controls

First-degree relatives of controls

Eligibility Criteria

Age40 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

The participants in this proposed study will be recruited from our on-going family cohort of RBD

You may qualify if:

Chinese aged 40 or above;

Sponsors & Collaborators

Chinese University of Hong Kong
Otherlead

Study Sites (1)

Department of psychiatry, Faculty of Medicine, The Chinese University of Hong Kong

Hong Kong, Hong Kong

Biospecimen

Retention: SAMPLES WITH DNA

Thyroid Function Tests(TFT), Vitamin B12, Folate, Complete Blood Count(CBC), Fasting Glucose, Liver Function Tests(LFT), Renal Function Tests(RFT), C-reactive protein(CRP), Fasting lipid, Iron profile, Phosphate, Calcium, Neurosteroid, Genetic analysis

MeSH Terms

Conditions

REM Sleep Behavior DisorderNerve Degeneration

Condition Hierarchy (Ancestors)

REM Sleep ParasomniasParasomniasSleep Wake DisordersNervous System DiseasesMental DisordersPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Jihui Zhang, PhD
Chinese University of Hong Kong
PRINCIPAL INVESTIGATOR
Yun Kwok Wing, MBChB
Chinese University of Hong Kong
STUDY DIRECTOR
Vincent Chung Tong Mok, MBChB
Chinese University of Hong Kong
STUDY DIRECTOR
Shirley Xin Li, PhD
Hong Kong University
STUDY DIRECTOR

Enrollment

170 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Assistant Professor

Study Record Dates

First Submitted

August 30, 2018

First Posted

September 14, 2018

Study Start

September 27, 2018

Actual (reported)

Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (2)

FDRs of idiopathic RBD patients

FDRs of controls

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (2)

FDRs of idiopathic RBD patients

FDRs of controls

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations